36. Epidermolysis bullosa Clinical trials / Disease details
Clinical trials : 160 / Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04917874 (ClinicalTrials.gov) | May 25, 2021 | 2/6/2021 | A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa | Open Label Treatment of Beremagene Geperpavec (B-VEC) | Dystrophic Epidermolysis Bullosa;DEB - Dystrophic Epidermolysis Bullosa;Recessive Dystrophic Epidermolysis Bullosa;Dominant Dystrophic Epidermolysis Bullosa | Biological: Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech, Inc. | NULL | Recruiting | 6 Months | N/A | All | 30 | Phase 3 | United States |